191602-84-3

Basic information

• Product Name: CHEMBRDG-BB 6451701
• Synonyms: CHEMBRDG-BB 6451701;3-BROMO-4-ISOPROPOXYBENZALDEHYDE;3-bromo-4-isopropoxybenzaldehyde(SALTDATA: FREE);3-bromo-4-(propan-2-yloxy)benzaldehyde;Benzaldehyde, 3-bromo-4-(1-methylethoxy)-
• CAS NO: 191602-84-3
• Molecular Formula: C₁₀H₁₁BrO₂
• Molecular Weight: 243.1
• Mol File: 191602-84-3.mol

Chemical Properties

• Boiling Point: 310.7°C at 760 mmHg
• Flash Point: 141.7°C
• Appearance: /
• Density: 1.391g/cm³
• Vapor Pressure: 0.00059mmHg at 25°C
• Refractive Index: 1.561
• Storage Temp.: 2-8°C
• CAS DataBase Reference: CHEMBRDG-BB 6451701(CAS DataBase Reference)
• NIST Chemistry Reference: CHEMBRDG-BB 6451701(191602-84-3)
• EPA Substance Registry System: CHEMBRDG-BB 6451701(191602-84-3)

Safety Data

• Hazardous Substances Data: 191602-84-3(Hazardous Substances Data)

Usage

Uses

Given the limited information available on CHEMBRDG-BB 6451701, it is challenging to list specific applications without further research or documentation. However, based on its chemical structure, it can be hypothesized that it may have potential uses in the following areas:
Used in Pharmaceutical Industry:
CHEMBRDG-BB 6451701 could be used as a starting material or intermediate in the synthesis of pharmaceutical compounds, given its unique cyclopentanol and chlorophenyl groups, which may offer specific binding or interaction properties with biological targets.
Used in Chemical Research:
In the field of chemical research, CHEMBRDG-BB 6451701 may serve as a subject for studying the effects of its structural features on chemical reactivity, stability, or other properties. This could contribute to the development of new synthetic methods or the understanding of structure-activity relationships in chemical compounds.
Used in Material Science:
The cyclopentanol derivative may also find applications in material science, potentially serving as a component in the development of new materials with specific properties, such as improved solubility, stability, or reactivity.

InChI:InChI=1/C10H11BrO2/c1-7(2)13-10-4-3-8(6-12)5-9(10)11/h3-7H,1-2H3

Upstream product

• 123-08-0 4-hydroxy-benzaldehyde 
• 75-30-9 2-iodo-propane 
• 2973-78-6 3-bromo-4-hydroxybenzylaldehyde 
• 75-26-3 isopropyl bromide 

Downstream Products

• 1289265-12-8 5-formyl-2-iso-propoxybenzonitrile 
• 454186-06-2 8-{4-[2-(ethoxycarbonyl-methyl-amino)-ethyl]-2-nitro-phenoxy}-1-[4-(2-isopropoxy-5-methoxycarbonyl-phenoxy)-benzyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester 
• 454185-87-6 3-[4-((S)-8-{4-[2-(Ethoxycarbonyl-methyl-amino)-ethyl]-2-methoxy-phenoxy}-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydro-isoquinolin-1-ylmethyl)-phenoxy]-4-isopropoxy-benzoic acid methyl ester 
• 454185-99-0 N-[2-(3-benzyloxy-4,5-dimethoxy-phenyl)-ethyl]-2-{4-[5-(tert-butyl-dimethyl-silanyloxymethyl)-2-isopropoxy-phenoxy]-phenyl}-N-(1-phenyl-ethyl)-acetamide 
• 454186-14-2 3-{4-[(S)-6,7-Dimethoxy-8-(6-methoxy-2-methyl-1-oxo-1,2,3,4-tetrahydro-isoquinolin-7-yloxy)-2-methyl-1,2,3,4-tetrahydro-isoquinolin-1-ylmethyl]-phenoxy}-4-isopropoxy-benzoic acid methyl ester 
• 454186-03-9 3-{4-[(S)-8-Benzyloxy-6,7-dimethoxy-2-((S)-1-phenyl-ethyl)-1,2,3,4-tetrahydro-isoquinolin-1-ylmethyl]-phenoxy}-4-isopropoxy-benzoic acid methyl ester 
• 454186-01-7 3-(4-{[[2-(3-Benzyloxy-4,5-dimethoxy-phenyl)-ethyl]-((S)-1-phenyl-ethyl)-carbamoyl]-methyl}-phenoxy)-4-isopropoxy-benzoic acid 
• 454186-12-0 3-(4-{[[2-(3-Benzyloxy-4,5-dimethoxy-phenyl)-ethyl]-((S)-1-phenyl-ethyl)-carbamoyl]-methyl}-phenoxy)-4-isopropoxy-benzoic acid methyl ester 
• 454186-11-9 N-[2-(3-benzyloxy-4,5-dimethoxy-phenyl)-ethyl]-2-[4-(5-hydroxymethyl-2-isopropoxy-phenoxy)-phenyl]-N-(1-phenyl-ethyl)-acetamide 

Relevant articles and documents

NOVEL HETEROCYCLIC COMPOUNDS AS IRAK4 INHIBITORS

The present invention relates to novel compounds of the general formula (I) their tautomeric forms, their enantiomers, their diastereoisomers, their pharmaceutically accepted salts, or pro-drugs thereof, which are useful for the treatment or prevention of cancer and inflammatory diseases associated with Interleukin-1 Receptor Associated Kinase (IRAK), and more particularly compounds that modulate the function of IRAK4.

BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS

Compounds, tautomers and pharmaceutically acceptable salts of the compounds of Formula (Ia) are disclosed which are inhibitors of lnterleukin-1 receptor associated kinase (IRAK4). Methods of treatment, methods of synthesis, and intermediates are also disclosed as defined in the specification.

Bicyclic-Fused Heteroaryl or Aryl Compounds

Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Synthesis and evaluation of 1-hydroxy/methoxy-4-methyl-2-phenyl-1 H-imidazole-5-carboxylic acid derivatives as non-purine xanthine oxidase inhibitors

Xanthine oxidase is a key enzyme that catalyses hypoxanthine and xanthine to uric acid, whose overproduction leads to the gout-causing hyperuricemia. In this study, a series of 1-hydroxy/methoxy-4-methyl-2-phenyl-1H-imidazole-5-carboxylic acid derivatives (4ae4k and 6ae6k) was synthesized and evaluated for their inhibitory potency against xanthine oxidase. The 1-hydroxyl substituted derivatives 4ae4k showed excellent inhibitory potency with IC50 values ranging from 0.003 μM to 1.2 μM, with compounds 4d (IC50= 0.003 μM), 4e (IC50 = 0.003 μM), and 4f (IC50 = 0.006 μM) manifesting the most potent xanthine oxidase inhibitory potency that were comparable with that of Febuxostat (IC50 = 0.01 μM). LineweavereBurk plot analysis revealed that representative compound 4f acted as a mixed-type inhibitor for xanthine oxidase. The basis of significant inhibition of xanthine oxidase by 4f was rationalized by its molecular docking into the active site of xanthine dehydrogenase.

INHIBITORS OF ACETYL-COA CARBOXYLASE

The present invention relates to compounds that act as acetyl-CoA carboxylase (ACC) inhibitors. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.

AMINOPHENYLPROPANOIC ACID DERIVATIVE

A compound represented by the formula (1): wherein each symbol is as defined in the specification, and a salt thereof and a prodrug thereof unexpectedly have superior GPR40 receptor agonist activity, superior in the properties as a pharmaceutical product such as stability and the like, and can be a safe and useful pharmaceutical agent as a drug for the prophylaxis or treatment of GPR40 receptor related pathology or diseases such as diabetes and the like.

First enantioselective total synthesis of (-)-tejedine

(Matrix presented) The first enantioselective total synthesis of (-)-tejedine (1) is reported. Tejedine is a seco-bisbenzyltetrahydroisoquinoline isolated in 1998 as a minor component from Berberis vulgaris. The synthesis was achieved using a strategy employing four key steps, including a chiral auxiliary-assisted diastereoselective Bischler-Napieralski cyclization.